Sanofi India on Wednesday reported a decline of 20.1 per cent in net profit to ₹190.4 crore, This is against a net profit of ₹238.4 crore in the corresponding quarter last fiscal.
The revenue from operations rose by 4.2 per cent to ₹736.5 crore in the quarter under review from ₹707 crore in the year ago period, said Sanofi India in its regulatory filing.
The operating profit, i.e., earnings before interest and tax, depreciation and amortization (EBITDA) was up by 18.2 per cent to ₹230 crore as against ₹194.5 crore in the year ago period, while the EBITDA margin came in at 31.2 per cent as against 27.5 per cent in the year ago period.
Sanofi India board has also approved the demerger of its consumer healthcare business into a wholly-owned subsidiary of the company.
The consumer healthcare business of the company includes assets, liabilities and all other aspects pertaining to the consumer healthcare business including brands like Allegra, Combiflam, DePURA , Avil, and others.
The turnover of the consumer healthcare undertaking of Sanofi India for the financial year ended 31st December 2022 was approximately ₹728 crore, representing 28 per cent of the total turnover of the company for the said year.
The company's share was up 1.62 per cent at ₹5,675 on BSE.
